These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 22586017)

  • 1. Successful treatment of antineutrophil cytoplasmic antibody-associated vasculitis with eicosapentaenoic acid.
    Hirahashi J; Jo A; Ueda K; Tojo A; Fujita T
    Ann Intern Med; 2012 May; 156(10):755-6. PubMed ID: 22586017
    [No Abstract]   [Full Text] [Related]  

  • 2. Anti-CD20 therapy and pauci-immune crescentic glomerulonephritis.
    Shu KH; Chiang WC; Chiu YL
    J Formos Med Assoc; 2017 Apr; 116(4):215-216. PubMed ID: 26786252
    [No Abstract]   [Full Text] [Related]  

  • 3. Refractory disease in antineutrophil cytoplasmic antibodies associated vasculitis.
    Rutgers A; Kallenberg CG
    Curr Opin Rheumatol; 2012 May; 24(3):245-51. PubMed ID: 22410545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B-cell depleting agents for ANCA vasculitides: a new therapeutic approach.
    Gómez-Puerta JA; Quintana LF; Stone JH; Ramos-Casals M; Bosch X
    Autoimmun Rev; 2012 Jul; 11(9):646-52. PubMed ID: 22146313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab for rescue and maintenance therapy in rapidly progressive life-threatening antineutrophil cytoplasmic autoantibody-associated systemic vasculitis.
    José RJ; Chrysochou C; Shurrab AE; New D; Wood GN
    Scand J Urol Nephrol; 2010 Dec; 44(6):459-62. PubMed ID: 20645677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding the role of rituximab in ANCA GN: regressing toward the mean.
    Pendergraft WF; Falk RJ
    J Am Soc Nephrol; 2015 Apr; 26(4):771-4. PubMed ID: 25381425
    [No Abstract]   [Full Text] [Related]  

  • 7. Tubular lesions predict renal outcome in antineutrophil cytoplasmic antibody-associated glomerulonephritis after rituximab therapy.
    Berden AE; Jones RB; Erasmus DD; Walsh M; Noël LH; Ferrario F; Waldherr R; Bruijn JA; Jayne DR; Bajema IM;
    J Am Soc Nephrol; 2012 Feb; 23(2):313-21. PubMed ID: 22095945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis.
    Smith RM; Jones RB; Guerry MJ; Laurino S; Catapano F; Chaudhry A; Smith KG; Jayne DR
    Arthritis Rheum; 2012 Nov; 64(11):3760-9. PubMed ID: 22729997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Itraconazole as a novel addition to ANCA-associated vasculitides or other neutrophilic dermatosis armamentarium.
    Pazyar N; Feily A
    Minerva Med; 2010 Dec; 101(6):458-9. PubMed ID: 21196906
    [No Abstract]   [Full Text] [Related]  

  • 10. Summary for Patients: Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
    Ann Intern Med; 2020 Aug; 173(3):I18. PubMed ID: 32479170
    [No Abstract]   [Full Text] [Related]  

  • 11. ANCA-positive pauci-immune rapidly progressive glomerulonephritis and the nephrotic syndrome.
    Jabur WL; Saeed HM
    Saudi J Kidney Dis Transpl; 2010 May; 21(3):526-30. PubMed ID: 20427883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab associated pneumonitis in antineutrophil cytoplasmic antibody-associated vasculitis.
    Arulkumaran N; Suleman R; Cecconi M; Kiely P; Chua F
    J Clin Rheumatol; 2012 Jan; 18(1):39-41. PubMed ID: 22157278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On ANCA-associated glomerulonephritis in the very elderly.
    Reschen ME
    Kidney Int; 2011 Nov; 80(10):1107; author reply 1107. PubMed ID: 22042032
    [No Abstract]   [Full Text] [Related]  

  • 14. Recent advances to achieve remission induction in antineutrophil cytoplasmic antibody-associated vasculitis.
    Harper L
    Curr Opin Rheumatol; 2010 Jan; 22(1):37-42. PubMed ID: 19770660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extracapillary glomerulonephritis type I with the coexistence of positive anti-GBM and p-ANCA antibodies.
    Toledo Perdomo K; Ortega Salas R; Pérez-Sáez MJ; Esquivias de Motta E; Espinosa Hernández M; López Andreu M; López Rubio F; Aljama García P
    Nefrologia; 2011; 31(1):113-5. PubMed ID: 21270926
    [No Abstract]   [Full Text] [Related]  

  • 16. Off-trial evaluation of the B cell-targeting treatment in the refractory cases of antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: long-term follow-up from a single centre.
    Pullerits R; Ljevak M; Vikgren J; Bokarewa M
    Scand J Immunol; 2012 Oct; 76(4):411-20. PubMed ID: 22823472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Skin rash in a patient with antineutrophil cytoplasmic antibody vasculitis.
    Yamada H; Ito M; Tsukamoto T; Yanagita M
    Kidney Int; 2017 Jul; 92(1):269. PubMed ID: 28646998
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical efficacy of intravenous immunoglobulin for patients with MPO-ANCA-associated rapidly progressive glomerulonephritis.
    Ito-Ihara T; Ono T; Nogaki F; Suyama K; Tanaka M; Yonemoto S; Fukatsu A; Kita T; Suzuki K; Muso E
    Nephron Clin Pract; 2006; 102(1):c35-42. PubMed ID: 16174989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term patient survival in ANCA-associated vasculitis.
    Flossmann O; Berden A; de Groot K; Hagen C; Harper L; Heijl C; Höglund P; Jayne D; Luqmani R; Mahr A; Mukhtyar C; Pusey C; Rasmussen N; Stegeman C; Walsh M; Westman K;
    Ann Rheum Dis; 2011 Mar; 70(3):488-94. PubMed ID: 21109517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effectiveness of regimens of remission-induction on vasculitis associated with antineutrophil cytoplasmic antibodies].
    Arenzana CB
    Rev Clin Esp (Barc); 2014 Mar; 214(2):103. PubMed ID: 24772475
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.